Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 9 unusual trades.
Delving into the details, we found 55% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $353,060, and 7 were calls, valued at $317,256.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $50.0 for Viking Therapeutics during the past quarter.
Volume & Open Interest Development
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Viking Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Viking Therapeutics's whale trades within a strike price range from $20.0 to $50.0 in the last 30 days.
Viking Therapeutics Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | PUT | SWEEP | BULLISH | 08/15/25 | $2.89 | $2.56 | $2.7 | $20.00 | $270.2K | 183 | 1 |
| VKTX | CALL | SWEEP | BULLISH | 04/17/25 | $2.34 | $1.93 | $1.93 | $32.50 | $91.3K | 345 | 501 |
| VKTX | PUT | TRADE | BULLISH | 01/16/26 | $11.35 | $9.3 | $9.74 | $30.00 | $82.7K | 821 | 85 |
| VKTX | CALL | SWEEP | BEARISH | 03/21/25 | $1.68 | $1.5 | $1.5 | $30.00 | $56.5K | 2.1K | 410 |
| VKTX | CALL | SWEEP | BEARISH | 01/15/27 | $7.35 | $6.5 | $6.7 | $50.00 | $51.5K | 755 | 86 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Present Market Standing of Viking Therapeutics
- Currently trading with a volume of 1,697,510, the VKTX's price is down by -6.69%, now at $26.94.
- RSI readings suggest the stock is currently may be approaching oversold.
- Anticipated earnings release is in 51 days.
What Analysts Are Saying About Viking Therapeutics
5 market experts have recently issued ratings for this stock, with a consensus target price of $99.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Viking Therapeutics, targeting a price of $71. * An analyst from Scotiabank downgraded its action to Sector Outperform with a price target of $102. * In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $102. * Consistent in their evaluation, an analyst from Raymond James keeps a Strong Buy rating on Viking Therapeutics with a target price of $125. * An analyst from B. Riley Securities downgraded its action to Buy with a price target of $96.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
